[1]
N. Turnšek, “Real-world outcomes, treatment patterns and T790M testing rates in Non-Small Cell Lung Cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT: Outcomes and treatments of EGFR-mutated NSCLC patients from Slovenia”, RO, vol. 56, no. 3, pp. 371–379, Sep. 2022.